NCT00144976View on ClinicalTrials.gov

Study of Biological Effect of Tarceva (OSI-774) for Patients Stricken by ENT Epidermoid Carcinoma

NACompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

December 31, 2006

Study Completion Date

December 31, 2006

Conditions
Head and Neck Neoplasms
Interventions
DRUG

Tarceva

Tarceva will be administered at dosage 150 mg od one hour before or two hours after meat. Patients will receive Tarceva between 18 and 28 days.

Trial Locations (2)

Unknown

Center Oscar Lambret, Lille

Institut claudius regaud, Toulouse

All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

lead

Institut Claudius Regaud

OTHER

NCT00144976 - Study of Biological Effect of Tarceva (OSI-774) for Patients Stricken by ENT Epidermoid Carcinoma | Biotech Hunter | Biotech Hunter